The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients with Type 2 Diabetes
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Introduction Microalbuminuria and hypertension are risk factors for the development of diabetic nephropathy. Blockade of the renin-angiotensin system reduces progression to diabetic nephropathy in type 1 diabetic patients, whereas similar data are lacking for hypertensive type 2 diabetic subjects. We evaluated the renoprotective effect of an angiotensin II receptor antagonist, irbesartan, in hypertensive type 2 diabetic patients with microalbuminuria. Material and methods Five hundred and ninety hypertensive type 2 diabetic patients with microalbuminuria were enrolled in this multinational, randomised, double-blind, placebo-controlled study of irbesartan 150 mg/daily or 300 mg/daily or matching placebo for two years. The primary outcome was time to progression to diabetic nephropathy, defined as a persistent overnight albuminuria > 200 micrograms/min and at least a 30 per cent increase from baseline. Results Baseline characteristics in the three groups were similar. Ten patients (5.2 per cent) receiving irbesartan 300 mg and 19 patients (9.7 per cent) receiving irbesartan 150 mg daily reached the primary end point, as compared to 30 (14.9 per cent) patients on placebo (hazard ratio 0.30 [95 per cent confidence interval 0.14 to 0.61], p Discussions Irbesartan is renoprotective independently of its blood pressure lowering effect in type 2 diabetic subjects with microalbuminuria. It is safe and well tolerated.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Antihypertensive therapy reduces the risk of albuminuria (67)(68)(69)(70), and among people with type 1 or 2 diabetes with established CKD (eGFR <60 mL/min/1.73m 2 and UACR $300 mg/g creatinine), ACE inhibitor or ARB therapy reduces the risk of progression to ESKD (71)(72)(73)(74)(75)(76)(77)(78)(79)(80).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [77]
In the citing paper
“In the setting of lower levels of albuminuria (30-299 mg/g creatinine), ACE inhibitor or ARB therapy at maximum tolerated doses in trials has reduced progression to more advanced albuminuria ($300 mg/g creatinine), slowed CKD progression, and reduced cardiovascular events but has not reduced progression to ESKD (74,77).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [77]
In the citing paper
“The IRMA-2 study showed that treatment with irbesartan, an ARB, was associated with a dose-dependent reduction in the risk of progression of CKD, with an almost 3-fold risk reduction with the highest dose (300 mg per day) at 2 years of followup.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [11]
In the citing paper
“This effect was independent of the blood pressure -lowering properties of irbesartan.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [11]
In the citing paper
“In this regard, it should be noted that in related studies in patients with type 1 and type 2 diabetes, 1,28,29 the benefits of captopril or irbesartan were not tested in the presence of concurrent calcium-channel-antagonist therapy.”
From Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy (2001) · cites this paper as [29]
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Pitt, B., Poole-Wilson, P. A., Segal, R., Martinez, F. A., Dickstein, K., Camm, A. J., Konstam, M. A., Riegger, G., Klinger, G. H., Neaton, J., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02213-3 · Cited by 1,961
The Effect of Age on Creatinine Clearance in Men: A Cross-sectional and Longitudinal Study
Rowe, J. W., Andres, R., Tobin, J. D., Norris, A. H., & Shock, N. W. (1976) · Journal of Gerontology · doi:10.1093/geronj/31.2.155 · Cited by 1,104
Gæde, P., Vedel, P., Parving, H.-H., & Pedersen, O. (1999) · The Lancet · doi:10.1016/s0140-6736(98)07368-1 · Cited by 981
Self-citationTatti, P., Pahor, M., Byington, R. P., Mauro, P. D., Guarisco, R., Strollo, G., & Strollo, F. (1998) · Diabetes Care · doi:10.2337/diacare.21.4.597 · Cited by 850
Ravid, M., Savin, H., Jutrin, I., Bental, T., Katz, B., & Lishner, M. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-118-8-199304150-00001 · Cited by 775
Research works printed but not linked: 9
- Parving H-H, Østerby R, Ritz E. Diabetic nephropathy. In: Brenner BM, ed. The kidney. 6th ed. Philadelphia: W.B. Saunders, 2000:1731-73.
- Hofman W, 1989, Lab Med, 13, 470
- Seelig HP, 1969, Z Klin Chem Klin Biochem, 7, 581
- Goldstein DE, 1986, Clin Chem, 32, B64
- 10.1001/jama.271.4.275 · doi:10.1001/jama.271.4.275 · Paper page
- 10.2307/2281868 · doi:10.2307/2281868 · Paper page
- Mantel N, 1959, J Natl Cancer Inst, 27, 719
- Agardh C-D, 1996, J Hum Hypertens, 10, 185
- Estacio RO, 2000, Diabetes Care, 23, B54
Cited by
Items 401–500 of 1,008
Andersen, S., Mischak, H., Zürbig, P., Parving, H., & Rossing, P. R. (2010) · BMC Nephrology · doi:10.1186/1471-2369-11-29 · Cited by 87
Self-citationAndersen, S., Brøchner‐Mortensen, J., Parving, H., & Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria Study Group (2003) · Diabetes Care · doi:10.2337/diacare.26.12.3296 · Cited by 84
Self-citationAlbuminuria: A Target for Treatment of Type 2 Diabetic Nephropathy
de Zeeuw, D. (2007) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2007.01.002 · Cited by 89
Santos, P. C. J. L., Krieger, J. E., & Pereira, A. C. (2012) · Journal of Pharmacological Sciences · doi:10.1254/jphs.12r03cr · Cited by 103
Proteome Analysis of Serum from Type 2 Diabetics with Nephropathy
Kim, H.-J., Cho, E.-H., Yoo, J.-H., Kim, P.-K., Shin, J., Kim, M.-R., & Kim, C. (2007) · Journal of Proteome Research · doi:10.1021/pr060489g · Cited by 84
Kidney aging—inevitable or preventable?
Choudhury, D., & Levi, M. (2011) · Nature Reviews Nephrology · doi:10.1038/nrneph.2011.104 · Cited by 89
“Use of ACE inhibitors and ARBs in patients with diabetic and nondiabetic proteinuria is beneficial in decreasing the rate of GFR loss”
MethodComparative effectiveness of incident oral antidiabetic drugs on kidney function
Hung, A. M., Roumie, C. L., Greevy, R. A., Liu, X., Grijalva, C. G., Murff, H. J., Ikizler, T. A., & Griffin, M. R. (2012) · Kidney International · doi:10.1038/ki.2011.444 · Cited by 85
Prevalence of albuminuria in Australia: The AusDiab Kidney Study
Atkins, R. C., Polkinghorne, K. R., Briganti, E. M., Shaw, J. E., Zimmet, P., & Chadban, S. J. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.09206.x · Cited by 83
Di Cesare, M., Bennett, J. E., Best, N., Stevens, G. A., Danaei, G., & Ezzati, M. (2013) · International Journal of Epidemiology · doi:10.1093/ije/dyt063 · Cited by 83
Kincaid‐Smith, P., Fairley, K., & Packham, D. (2002) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/17.4.597 · Cited by 84
Seidu, S., Kunutsor, S. K., Cos, X., Gillani, S., & Khunti, K. (2018) · Primary Care Diabetes · doi:10.1016/j.pcd.2018.02.001 · Cited by 82
Therapeutic Insights in Chronic Kidney Disease Progression
Shabaka, A., Cases‐Corona, C., & Juarez, G. M. F. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.645187 · Cited by 96
Persson, F., Rossing, P. R., Hovind, P. H., Stehouwer, C. D. A., Schalkwijk, C. G., Tarnow, L., & Parving, H. (2006) · Diabetes · doi:10.2337/db06-0827 · Cited by 86
Self-citationPimagedine: a novel therapy for diabetic nephropathy
Bolton, W. K., & Abdel-Rahman, E. (2002) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.11.4.565 · Cited by 82
Gilbert, R. E., Krum, H., Wilkinson‐Berka, J. L., & Kelly, D. J. (2003) · Diabetic Medicine · doi:10.1046/j.1464-5491.2003.00979.x · Cited by 105
Banerjee, D., Winocour, P. H., Chowdhury, T. A., De, P., Wahba, M. M., Montero, R., Fogarty, D. G., Frankel, A., Karalliedde, J. J., Mark, P. B., et al. (2022) · BMC Nephrology · doi:10.1186/s12882-021-02587-5 · Cited by 108
Plasma aldosterone concentration in the patient with diabetes mellitus Rapid Communication
Hollenberg, N. K., Stevanovic, R. D., Agarwal, A., Lansang, M. C., Price, D. A., Laffel, L. M., Williams, G. H., & Fisher, N. D. L. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00524.x · Cited by 81
Medical Care Costs Associated With Progression of Diabetic Nephropathy
Nichols, G. A., Vupputuri, S. X., & Lau, H. (2011) · Diabetes Care · doi:10.2337/dc11-0475 · Cited by 81
The economic burden of progressive chronic kidney disease among patients with type 2 diabetes
Vupputuri, S. X., Kimes, T. M., Calloway, M. O., Christian, J. B., Bruhn, D. F., Martin, A. A., & Nichols, G. A. (2013) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2013.09.014 · Cited by 82
Formononetin attenuates kidney damage in type 2 diabetic rats
Oza, M. J., & Kulkarni, Y. A. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.01.013 · Cited by 87
Persson, F., Rossing, P. R., Hovind, P. H., Stehouwer, C. D. A., Schalkwijk, C. G., Tarnow, L., & Parving, H. (2008) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365510802187226 · Cited by 88
Self-citationImprovements in the Management of Diabetic Nephropathy
Dounousi, E. C., Duni, Α., Leivaditis, K., Vaios, V., Eleftheriadis, T., & Liakopoulos, V. (2015) · The Review of Diabetic Studies · doi:10.1900/rds.2015.12.119 · Cited by 90
Thomopoulos, C., Parati, G., & Zanchetti, A. (2016) · Journal of Hypertension · doi:10.1097/hjh.0000000000000972 · Cited by 79
Ruggenenti, P., Fassi, A., Ilieva, A. P., Iliev, I. P., Chiurchiu, C., Rubis, N., Gherardi, G., Ene-Iordache, B., Gaspari, F., Perna, A., et al. (2011) · Journal of Hypertension · doi:10.1097/hjh.0b013e32834069bd · Cited by 79
Microalbuminuria and risk factors in type 1 and type 2 diabetic patients
Cederholm, J., Eliasson, B., Nilsson, P.-E., Weiss, L. G., & Guðbjörnsdóttir, S. (2004) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2004.07.021 · Cited by 80
Guías de práctica clínica para el tratamiento de la hipertensión arterial 2007
(ESH), G. D. T. P. E. T. D. L. H. A. D. L. S. E. D. H., & de Cardiología, D. L. S. E. (2007) · Revista Española de Cardiología · doi:10.1157/13109650 · Cited by 100
Cerasola, G., Cottone, S., & Mulè, G. (2010) · Journal of Hypertension · doi:10.1097/hjh.0b013e32833ec377 · Cited by 79
on behalf of the ADVANCE Collaborative Group, Oshima, M., Jun, M., Ohkuma, T., Toyama, T., Wada, T., Cooper, M. E., Hadjadj, S., Hamet, P., Harrap, S. B., et al. (2019) · Diabetologia · doi:10.1007/s00125-019-4948-4 · Cited by 87
Irbesartan: A Review of its Use in Hypertension and in the Management of Diabetic Nephropathy
Croom, K. F., Curran, M. P., Goa, K. L., & Perry, C. M. (2004) · Drugs · doi:10.2165/00003495-200464090-00011 · Cited by 88
Nelson, A. J., O’Brien, E. C., Kaltenbach, L. A., Green, J. B., Lopes, R. D., Morse, C. G., Al-Khalidi, H. R., Aroda, V. R., Cavender, M. A., Gaynor, T., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.48030 · Cited by 78
Cardiovascular Disease in Diabetes and Chronic Kidney Disease
Swamy, S., Noor, S. M., & Mathew, R. O. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12226984 · Cited by 96
“…Diabetic Nephropathy Trial (IDNT) and in the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan Study (RENAAL), both of which demonstrated lower risk for progression to ESKD and serum creatinine doubling time with the use of irbesartan or losartan, respectively [35,36].”
BackgroundZheng, F., Zeng, Y.-J., Plati, A. R., Elliot, S. J., Berho, M. E., Potier, M., Striker, L. J., & Striker, G. E. (2006) · Kidney International · doi:10.1038/sj.ki.5001578 · Cited by 79
Mischak, H., Delles, C., Klein, J., & Schanstra, J. P. (2010) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2010.09.004 · Cited by 84
Prevalence, Consequences, and Implications for Clinical Trials of Unrecognized Myocardial Infarction
Pride, Y. B., Piccirillo, B. J., & Gibson, C. M. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.11.042 · Cited by 82
Cardiovascular disease in chronic kidney disease from a cardiologistʼs perspective
McCullough, P. A. (2004) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-200411000-00003 · Cited by 90
Systems biology of kidney diseases
He, C., Chuang, P. Y., Ma’ayan, A., & Iyengar, R. (2011) · Kidney International · doi:10.1038/ki.2011.314 · Cited by 92
“…promising results, the only successful examples are studies using angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, 107–111 whereas many trials including aminoguanidine 112,113 and sulodexide (http://clinicaltrials.gov identifier NCT00130208) failed in phase III…”
BackgroundLercanidipine in Patients with Chronic Renal Failure: The ZAFRA Study
Robles, N. R., Ocón, J., Gomez, C. F., Manjón, M., Pastor, L., Herrera, J., Villatoro, J., Calls, J., Torrijos, J., Rodríguez, V. I., et al. (2005) · Renal Failure · doi:10.1081/jdi-200042801 · Cited by 78
Update on microalbuminuria as a biomarker in renal and cardiovascular disease
Heerspink, H. J. L., Brinkman, J. W., Bakker, S. J. L., Gansevoort, R. T., & de Zeeuw, D. (2006) · Current Opinion in Nephrology & Hypertension · doi:10.1097/01.mnh.0000247496.54882.3f · Cited by 88
Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies
Luño, J., Barrio, V., Goicoechea, M. Á., González, C., de Vinuesa, S. G., Gómez-Preciado, F., Bernis, C., Espinosa, M., Ahijado, F. J., Gómez, J., et al. (2002) · Kidney International · doi:10.1046/j.1523-1755.62.s82.10.x · Cited by 78
McBrien, K. A., Manns, B. J., Chui, B., Klarenbach, S. W., Rabi, D., Ravani, P., Hemmelgarn, B., Wiebe, N., Au, F., & Clement, F. (2013) · Diabetes Care · doi:10.2337/dc12-0862 · Cited by 77
Microalbuminuria in Type 2 Diabetics: An Important, Overlooked Cardiovascular Risk Factor
Weir, M. R. (2004) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2004.02524.x · Cited by 91
Taguchi, I., Toyoda, S., Takano, K., Arikawa, T., Kikuchi, M., Ogawa, M., Abe, S., Node, K., & Inoue, T. (2013) · Hypertension Research · doi:10.1038/hr.2013.3 · Cited by 81
Histone Deacetylase Inhibitors and Diabetic Kidney Disease
Hadden, M. J., & Advani, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092630 · Cited by 83
Hernández‐Madrid, A., Marín, I., Cervantes, C. E., Bernal, E., Estévez, J. E., Moreno, G., Rondón, J., Peng, J., Limón, L., Nannini, S., et al. (2004) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.3317/jraas.2004.027 · Cited by 77
Risk of End-Stage Renal Disease and Death After Cardiovascular Events in Chronic Kidney Disease
Sud, M. K., Tangri, N., Pintilie, M., Levey, A. S., & Naimark, D. M. J. (2014) · Circulation · doi:10.1161/circulationaha.113.007106 · Cited by 85
Regression of Advanced Diabetic Nephropathy by Hepatocyte Growth Factor Gene Therapy in Rats
Cruzado, J. M., Lloberas, N., Torrás, J., Riera, M., Fillat, C., Herrero, I., Aran, J. M., Alperovich, G., Vidal, A., & Grinyo, J. M. (2004) · Diabetes · doi:10.2337/diabetes.53.4.1119 · Cited by 76
Iino, Y., Hayashi, M., Kawamura, T., Shiigai, T., Tomino, Y., Yamada, K., KITAJIMA, T., Ideura, T., Kôyama, A., Sugisaki, T., et al. (2004) · Hypertension Research · doi:10.1291/hypres.27.21 · Cited by 76
Aranda, P. J., Segura, J., Ruilope, L. M., Aranda, F. J., Frutos, M. Á., López, V., & de Novales, E. L. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.08.034 · Cited by 77
Mizuno, M., Sada, T., Kato, M., & Koike, H. (2002) · Hypertension Research · doi:10.1291/hypres.25.271 · Cited by 76
Improvement of albuminuria after renal denervation
Ott, C., Mahfoud, F., Schmid, A., Ditting, T., Veelken, R., Ewen, S., Ukena, C., Uder, M., Böhm, M., & Schmieder, R. E. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.03.017 · Cited by 75
The frail renin–angiotensin system
Abadir, P. M. (2011) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2010.08.004 · Cited by 70
Yildirim, T., Arici, M., Piskinpasa, S., Aybal-Kutlugun, A., Yilmaz, R., Altun, B., Erdem, Y., & Turgan, C. (2012) · Renal Failure · doi:10.3109/0886022x.2012.717478 · Cited by 74
Cardiovascular risk factors in patients with chronic kidney disease
van der Zee, S. A., Baber, U., Elmariah, S., Winston, J. A., & Fuster, V. (2009) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2009.121 · Cited by 97
Horita, Y., Taura, K., Taguchi, T., Furusu, A., & Kohno, S. (2006) · Nephrology · doi:10.1111/j.1440-1797.2006.00665.x · Cited by 75
Twenty years after ACEIs and ARBs: emerging treatment strategies for diabetic nephropathy
Johnson, S. A., & Spurney, R. F. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00266.2015 · Cited by 79
Hellemons, M. E., Kerschbaum, J., Bakker, S. J. L., Neuwirt, H., Mayer, B., Mayer, G. J., de Zeeuw, D., Heerspink, H. J. L., & Rudnicki, M. (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03437.x · Cited by 99
“[29] in patients from the welldesigned randomized control trial ‘Irbesartan MicroAlbuminuria Type 2 Diabetes Mellitus in Hypertensive Patients’ (IRMA-2) [41].”
BackgroundPavkov, M. E., Knowler, W. C., Bennett, P. H., Looker, H. C., Krakoff, J. A., & Nelson, R. G. (2006) · Kidney International · doi:10.1038/sj.ki.5001882 · Cited by 84
Kojima, S., Shida, M., & Yokoyama, H. (2004) · Hypertension Research · doi:10.1291/hypres.27.379 · Cited by 82
Makino, H., Haneda, M., Babazono, T., Moriya, T., Ito, S., Iwamoto, Y., Kawamori, R., Takeuchi, M., & Katayama, S. (2008) · Hypertension Research · doi:10.1291/hypres.31.657 · Cited by 74
The renin-angiotensin system and insulin resistance
Liu, Z. (2007) · Current Diabetes Reports · doi:10.1007/s11892-007-0007-5 · Cited by 81
Sasso, F. C., Nicola, L. D., Carbonara, O., Nasti, R., Minutolo, R., Salvatore, T., Conte, G., Torella, R., & for the NID-2 (Nephropathy in Diabetes-Type 2) Study Group (2006) · Diabetes Care · doi:10.2337/diacare.29.03.06.dc05-1776 · Cited by 75
Burns, W. C., Velkoska, E., Dean, R. G., Burrell, L. M., & Thomas, M. C. (2010) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00538.2009 · Cited by 74
Sasso, F. C., Carbonara, O., Persico, M., Iafusco, D., Salvatore, T., D’Ambrosio, R., Torella, R., & Cozzolino, D. (2002) · Diabetes Care · doi:10.2337/diacare.25.11.1909 · Cited by 73
Time course and mechanisms of the anti‐hypertensive and renal effects of liraglutide treatment
von Scholten, B. J., Lajer, M., Goetze, J. P., Persson, F., & Rossing, P. (2015) · Diabetic Medicine · doi:10.1111/dme.12594 · Cited by 73
Comparison of Angiotensin II Type 1 Receptor Antagonists in the Treatment of Essential Hypertension
Smith, D. H. G. (2008) · Drugs · doi:10.2165/00003495-200868090-00003 · Cited by 72
Association of heart rate with microalbuminuria in cardiovascular risk patients: data from I-SEARCH
Böhm, M., Reil, J., Danchin, N., Thoenes, M., Bramlage, P., & Volpe, M. (2008) · Journal of Hypertension · doi:10.1097/hjh.0b013e3282f05c8a · Cited by 80
Prevention Conference VI: Diabetes and Cardiovascular Disease
Grundy, S. M., Garber, A. J., Goldberg, R. B., Havas, S., Holman, R. R., Lamendola, C. A., Howard, W. J., Savage, P. J., Sowers, J. R., & Vega, G. L. (2002) · Circulation · doi:10.1161/01.cir.0000014022.85836.96 · Cited by 95
Comper, W. D., & Osicka, T. M. (2005) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2005.01.012 · Cited by 83
Effect of Losartan on Microalbuminuria in Normotensive Patients with Type 2 Diabetes Mellitus
Zandbergen, A. A. M., Baggen, M. G. A., Lamberts, S. W. J., Bootsma, A. H., de Zeeuw, D., & Ouwendijk, R. J. T. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-2-200307150-00008 · Cited by 74
Does Microalbuminuria Predict Diabetic Nephropathy?
Parving, H.-H., Chaturvedi, N., Viberti, G. C., & Mogensen, C. E. (2002) · Diabetes Care · doi:10.2337/diacare.25.2.406 · Cited by 90
Self-citationSchievink, B., Kröpelin, T., Mulder, S., Parving, H. ‐., Remuzzi, G., Dwyer, J., Vemer, P., de Zeeuw, D., & Lambers Heerspink, H. J. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12583 · Cited by 72
Self-citationRossing, P. R., Agarwal, R., Anker, S. D., Filippatos, G. S., Pitt, B., Ruilope, L. M., Amod, A., Marre, M., Joseph, A., Lage, A. Z., et al. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14558 · Cited by 76
Perazella, M. A., & Setaro, J. F. (2003) · Journal of Nuclear Cardiology · doi:10.1067/mnc.2003.392 · Cited by 84
Prevalence and Awareness of CKD Among African Americans: The Jackson Heart Study
Flessner, M. F., Wyatt, S. B., Akylbekova, E. L., Coady, S., Fülöp, T., Lee, F., Taylor, H. A., & Crook, E. D. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.08.035 · Cited by 81
Cardiovascular Disease and Diabetic Kidney Disease
Maqbool, M., Cooper, M. E., & Jandeleit-Dahm, K. A. M. (2018) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2018.02.003 · Cited by 80
Bloomgarden, Z. T. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1506 · Cited by 86
Tissue Gene Expression of Renin-Angiotensin System in Human Type 2 Diabetic Nephropathy
Konoshita, T., Wakahara, S., Mizuno, S., Motomura, M., Aoyama, C., Makino, Y., Kawai, Y., Kato, N., Koni, I., Miyamori, I., et al. (2006) · Diabetes Care · doi:10.2337/diacare.29.04.06.dc05-1873 · Cited by 75
González‐Juanatey, J. R., Ramos, P. M., Arcos, F. S., Alonso, V. B., Padial, L. R., & Bertoméu, V. (2003) · Revista Española de Cardiología · doi:10.1016/s0300-8932(03)76904-8 · Cited by 101
Optimal Dose of Candesartan for Renoprotection in Type 2 Diabetic Patients With Nephropathy
Rossing, K., Christensen, P. K., Hansen, B. V., Carstensen, B., & Parving, H. (2003) · Diabetes Care · doi:10.2337/diacare.26.1.150 · Cited by 73
Self-citationRenal Protection in Hypertensive Patients: Selection of Antihypertensive Therapy
Wenzel, R. R. (2005) · Drugs · doi:10.2165/00003495-200565002-00005 · Cited by 76
Vijan, S. S. (2019) · Annals of Internal Medicine · doi:10.7326/aitc201911050 · Cited by 78
The heart, kidney, and brain as target organs in hypertension
Mensah, G. A., Croft, J. B., & Giles, W. H. (2002) · Cardiology Clinics · doi:10.1016/s0733-8651(02)00004-8 · Cited by 86
Animal Versus Plant Protein Meals in Individuals With Type 2 Diabetes and Microalbuminuria
Wheeler, M. L., Fineberg, S. E., Fineberg, N. S., Gibson, R. G., & Hackward, L. L. (2002) · Diabetes Care · doi:10.2337/diacare.25.8.1277 · Cited by 71
Elliott, W. J. (2006) · Yearbook of Cardiology · doi:10.1016/s0145-4145(07)70048-5 · Cited by 70
Pharmacotherapy for hypertension in adults aged 18 to 59 years
Musini, V. M., Gueyffier, F., Puil, L., Salzwedel, D. M., & Wright, J. M. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008276.pub2 · Cited by 71
Rosei, E. A., Rizzoni, D., Muiesan, M. L., Sleiman, I., Salvetti, M., Monteduro, C., & Porteri, E. (2005) · Journal of Hypertension · doi:10.1097/00004872-200502000-00027 · Cited by 71
Evidence‐based guide to slowing the progression of early renal insufficiency
Johnson, D. W. (2004) · Internal Medicine Journal · doi:10.1111/j.1444-0903.2004.t01-6-.x · Cited by 79
Mulè, G., Castiglia, A., Cusumano, C., Scaduto, E., Geraci, G., Altieri, D. C., Natale, E. D., Cacciatore, O., Cerasola, G., & Cottone, S. (2016) · Advances in experimental medicine and biology · doi:10.1007/5584_2016_85 · Cited by 89
Analysis of Factors Causing Hyperkalemia
Takaichi, K., Takemoto, F., Ubara, Y., & Mori, Y. (2007) · Internal Medicine · doi:10.2169/internalmedicine.46.6415 · Cited by 75
Malacco, E., Santonastaso, M., Varì, N. A., Gargiulo, A., Spagnuolo, V., Bertocchi, F., Palatini, P., & PREVAIL Study Investigators (2004) · Clinical Therapeutics · doi:10.1016/s0149-2918(04)90129-4 · Cited by 75
Davis, B. J., Cao, Z., de Gasparo, M., Kawachi, H., Cooper, M. E., & Allen, T. J. (2003) · Journal of Hypertension · doi:10.1097/00004872-200301000-00031 · Cited by 75
Leoncini, G., Viazzi, F. C., Cosmo, S. D., Russo, G. T., Fioretto, P., & Pontremoli, R. (2020) · Journal of Nephrology · doi:10.1007/s40620-020-00803-3 · Cited by 77
Telmisartan: A Different Angiotensin II Receptor Blocker Protecting a Different Population?
Burnier, M. (2009) · Journal of International Medical Research · doi:10.1177/147323000903700602 · Cited by 72
Brown, W. W., Collins, A., Chen, S., King, K., Molony, D. A., Gannon, M. R., Politoski, G., & Keane, W. F. (2003) · Kidney International · doi:10.1046/j.1523-1755.63.s83.11.x · Cited by 76
AT1 and AT2 receptor in the kidney: role in health and disease
Siragy, H. M. (2004) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2003.11.009 · Cited by 68
Ninčević, V., Kolarić, T. O., Roguljić, H., Kizivat, T., Smolić, M., & Bilić-Čurčić, I. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235831 · Cited by 77
Candesartan Cilexetil: An Update of its Use in Essential Hypertension
Easthope, S. E., & Jarvis, B. (2002) · Drugs · doi:10.2165/00003495-200262080-00016 · Cited by 82
Kaplan, N. M. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-12-200112180-00012 · Cited by 75
Li, P. K., Weening, J. J., Dirks, J., Lui, S. L., Szeto, C., Tang, S. C. W., Atkins, R. C., Mitch, W. E., Chow, K. M., D’Amico, G., et al. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.09401.x · Cited by 72
Prevalence and Management of Diabetic Nephropathy in Western Countries
Satirapoj, B., & Adler, S. G. (2015) · Kidney Diseases · doi:10.1159/000382028 · Cited by 80
Metadata
- Authors
- Parving, H.-H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R., Andersen, S., & Arner, P.
- Affiliations
- Steno Diabetes Center Copenhagen (DK)
- University Hospital Magdeburg (DE)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2001-09-20
- Volume
- 345
- Issue
- 12
- Pages
- 870-878
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2003670762
- Semantic Scholar
- bec1f00c2120232a55a25b7d846d63e92a3ff8fc
- Cited by
- 2,873
- References
- 26
- Citations by year
- 2026: 30 · 2025: 44 · 2024: 50 · 2023: 61 · 2022: 61 · 2021: 58 · 2020: 63 · 2019: 50 · 2018: 63 · 2017: 71 · 2016: 84 · 2015: 88 · 2014: 105 · 2013: 103 · 2012: 117
- FWCI
- 146.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Keywords
- irbesartan, diabetic nephropathy, type 2 diabetes, hypertension, microalbuminuria, renal protection, angiotensin receptor blockers, renin-angiotensin system blockade, albuminuria, blood pressure, dose comparison, adverse events, renin-angiotensin system inhibitors
- MeSH terms
- Irbesartan, Adult, Aged, Albuminuria, Antihypertensive Agents, Biphenyl Compounds, Creatinine, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Female, Humans, Hypertension, Male, Middle Aged, Tetrazoles, Proportional Hazards Models, Disease Progression, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.